ATE540933T1 - Pyrimidinverbindungen als interleukin-12 (il-12) inhibitoren - Google Patents
Pyrimidinverbindungen als interleukin-12 (il-12) inhibitorenInfo
- Publication number
- ATE540933T1 ATE540933T1 AT02804468T AT02804468T ATE540933T1 AT E540933 T1 ATE540933 T1 AT E540933T1 AT 02804468 T AT02804468 T AT 02804468T AT 02804468 T AT02804468 T AT 02804468T AT E540933 T1 ATE540933 T1 AT E540933T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- pyrimidine compounds
- nrc
- Prior art date
Links
- 102000013462 Interleukin-12 Human genes 0.000 title abstract 3
- 108010065805 Interleukin-12 Proteins 0.000 title abstract 3
- 229940117681 interleukin-12 Drugs 0.000 title 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003230 pyrimidines Chemical class 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 238000012261 overproduction Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/000,742 US6693097B2 (en) | 2001-11-30 | 2001-11-30 | Pyrimidine compounds |
| US10/192,347 US6660733B2 (en) | 2001-11-30 | 2002-07-10 | 2,4,6-trisubstituted-pyrimidine compounds |
| PCT/US2002/038161 WO2003047516A2 (en) | 2001-11-30 | 2002-11-27 | Pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540933T1 true ATE540933T1 (de) | 2012-01-15 |
Family
ID=21692824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02804468T ATE540933T1 (de) | 2001-11-30 | 2002-11-27 | Pyrimidinverbindungen als interleukin-12 (il-12) inhibitoren |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US6693097B2 (de) |
| JP (1) | JP2010248208A (de) |
| AT (1) | ATE540933T1 (de) |
| ES (1) | ES2377947T3 (de) |
| ZA (1) | ZA200404215B (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| BR0214809A (pt) * | 2001-11-30 | 2004-09-14 | Synta Pharmaceuticals Corp | Compostos de pirimidina |
| AU2003284142A1 (en) | 2002-10-15 | 2004-05-04 | Synta Pharmaceuticals Corp | Aromatic bicyclic heterocyles to modulate 1L-12 production |
| WO2005000404A2 (en) * | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| TW200530588A (en) | 2003-11-10 | 2005-09-16 | Synta Pharmaceuticals Corp | Compositions and methods for modulating c-Rel-dependent cytokine production |
| JP4851337B2 (ja) * | 2003-11-10 | 2012-01-11 | シンタ ファーマシューティカルズ コーポレーション | ヘテロアリールヒドラゾン化合物 |
| EP1687004A4 (de) * | 2003-11-10 | 2009-04-08 | Synta Pharmaceuticals Corp | Pyridin-verbindungen |
| CA2545340A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| TWI380816B (zh) * | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑 |
| AU2005262322B2 (en) * | 2004-07-01 | 2012-07-26 | Synta Pharmaceuticals Corp. | 2-substituted heteroaryl compounds |
| JP2008519850A (ja) * | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| WO2006053109A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| TW200630363A (en) * | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
| AU2005310143A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| WO2006128172A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| TW200804307A (en) * | 2005-10-27 | 2008-01-16 | Synta Pharmaceuticals Corp | Process for preparing mesylate salts of IL-12 inhibitory compounds |
| WO2008125691A2 (en) * | 2007-04-17 | 2008-10-23 | Novartis Ag | Ethers of naphtalene carboxylic acid amides as cancer cure |
| EP2197853B1 (de) | 2007-10-09 | 2011-11-09 | Dow AgroSciences LLC | Insektizide pyrimidinyl-aryl-hydrazone |
| ES2532119T3 (es) | 2007-10-09 | 2015-03-24 | Dow Agrosciences Llc | Derivados de azinilo sustituido insecticidas |
| EP2197857B1 (de) * | 2007-10-09 | 2013-03-06 | Dow AgroSciences LLC | (1,3,5)-triazinylphenylhydrazone als insektizid |
| US20110098267A1 (en) * | 2008-02-07 | 2011-04-28 | Synta Pharmaceuticals Corporation | Topical formulations for the treatment of psoriasis |
| PL3354650T3 (pl) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Związki przydatne jako inhibitory kinazy atr |
| WO2010074284A1 (ja) | 2008-12-26 | 2010-07-01 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| ES2587232T3 (es) | 2010-07-20 | 2016-10-21 | Vestaron Corporation | Triazinas y pirimidinas insecticidas |
| PH12013500763B1 (en) * | 2010-10-27 | 2018-07-04 | Prometic Pharma Smt Ltd | Phenylketone carboxylate compounds and pharmaceutical uses thereof |
| AU2015209133B2 (en) | 2014-01-24 | 2019-10-03 | AI Therapeutics, Inc. | Apilimod compositions and methods for using same |
| CN104163788A (zh) * | 2014-07-07 | 2014-11-26 | 湖南华腾制药有限公司 | 一种吡啶衍生物的制备方法 |
| ES2734081T3 (es) * | 2014-11-07 | 2019-12-04 | Ai Therapeutics Inc | Apilimod para el uso en el tratamiento de melanoma |
| CN107249638B (zh) | 2014-11-07 | 2021-05-14 | 人工智能治疗公司 | 阿匹莫德用于治疗肾癌 |
| US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| WO2019046316A1 (en) | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
| US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
| US20230135152A1 (en) | 2020-02-11 | 2023-05-04 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
| BR112023025552A2 (pt) | 2021-06-11 | 2024-02-27 | Orphai Therapeutics Inc | Composições estabilizadas de apilimod e usos das mesmas |
| US20250282767A1 (en) | 2022-05-02 | 2025-09-11 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706264B1 (en) | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
| CA2366932C (en) | 1999-04-15 | 2009-08-25 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US6384032B1 (en) | 1999-06-17 | 2002-05-07 | Shionogi Bioresearch Corp. | Inhibitors of IL-12 production |
| US6680315B2 (en) | 2000-06-15 | 2004-01-20 | Synta Pharmaceuticals Corp. | Triazine compounds |
| BR0214809A (pt) | 2001-11-30 | 2004-09-14 | Synta Pharmaceuticals Corp | Compostos de pirimidina |
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| JP4851337B2 (ja) | 2003-11-10 | 2012-01-11 | シンタ ファーマシューティカルズ コーポレーション | ヘテロアリールヒドラゾン化合物 |
| TWM281199U (en) * | 2005-05-06 | 2005-11-21 | Inventec Appliances Corp | Pointer pen having connection interface |
-
2001
- 2001-11-30 US US10/000,742 patent/US6693097B2/en not_active Expired - Lifetime
-
2002
- 2002-07-10 US US10/192,347 patent/US6660733B2/en not_active Expired - Lifetime
- 2002-11-26 US US10/305,039 patent/US6858606B2/en not_active Expired - Lifetime
- 2002-11-27 AT AT02804468T patent/ATE540933T1/de active
- 2002-11-27 ES ES02804468T patent/ES2377947T3/es not_active Expired - Lifetime
-
2003
- 2003-09-05 US US10/656,671 patent/US7067514B2/en not_active Expired - Lifetime
-
2004
- 2004-05-28 ZA ZA200404215A patent/ZA200404215B/en unknown
-
2005
- 2005-01-21 US US11/041,537 patent/US7470685B2/en not_active Expired - Lifetime
- 2005-07-29 US US11/193,001 patent/US7465725B2/en not_active Expired - Lifetime
-
2010
- 2010-06-08 JP JP2010130584A patent/JP2010248208A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7465725B2 (en) | 2008-12-16 |
| HK1068890A1 (en) | 2005-05-06 |
| ES2377947T3 (es) | 2012-04-03 |
| US7470685B2 (en) | 2008-12-30 |
| US6858606B2 (en) | 2005-02-22 |
| JP2010248208A (ja) | 2010-11-04 |
| US20030139403A1 (en) | 2003-07-24 |
| US20060025409A1 (en) | 2006-02-02 |
| US20040024206A1 (en) | 2004-02-05 |
| US20030114446A1 (en) | 2003-06-19 |
| ZA200404215B (en) | 2006-12-27 |
| US20050250787A1 (en) | 2005-11-10 |
| US7067514B2 (en) | 2006-06-27 |
| US20040048873A1 (en) | 2004-03-11 |
| US6693097B2 (en) | 2004-02-17 |
| US6660733B2 (en) | 2003-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI256953B (en) | Pyrimidine compounds | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| ES2188280T3 (es) | Acetales heteroaril-ciclicos. | |
| TNSN06019A1 (en) | Pharmaceutical compounds | |
| MXPA03011706A (es) | Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina. | |
| EP1288202A4 (de) | N-acyltetrahydroisochinolin-derivate | |
| DE69918422D1 (de) | Phthalazinone pde iii/iv hemmer | |
| ATE203747T1 (de) | 5-azabicyclo(3.1.0.)hexylalkyl-2-piperidone und - glutarimide als neurokinin receptor antagonisten. | |
| YU108791A (sh) | Pirazolopirimidinon antianginalna jedinjenja | |
| DE60314639D1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| EA200400674A1 (ru) | Соли e-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил)аллил)ацетамида, их получение и их применение против рака | |
| DK0594636T3 (da) | 3-aminopiperidinderivater og relaterede nitrogenholdige heterocykliske forbindelser | |
| PE20050080A1 (es) | Antagonistas del receptor opioide | |
| DE602006011434D1 (de) | Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer | |
| ATE357142T1 (de) | 7-aminotriazolopyrimidine zur bekämpfung von schadpilzen | |
| HRP20090071T3 (en) | Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors | |
| EA200301100A1 (ru) | Новые фталазиноны | |
| TW200502225A (en) | Heterocyclic compounds useful as nurr-1 activators | |
| DE60110896D1 (de) | Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion | |
| DE60127845D1 (de) | Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel | |
| DE60228098D1 (de) | Pyridin-substituierte furanderivate als raf-kinase inhibitoren | |
| FI922341A0 (fi) | Piperidin- och pyrrolidinderivat. | |
| AR056582A1 (es) | COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE | |
| CO5170520A1 (es) | Derivados de 4-(fenil sustituido)-2-piperazinil-pirimidin-(3,5-bistrifluoro-metil-bencil)- metil-amida | |
| DE60202669D1 (de) | 6-phenylbenzonaphthyidine |